 |
George Dranitsaris, Health Economist, discusses the development of a global pricing index for new cancer drugs in patients with metastatic colorectal cancer (mCRC). The application of this index to estimate a price based on cost effectiveness and the wealth of a nation would be important for opening dialogues between the key stake-holders and a better alternative to government mandated price cuts.
|
From:PersonalizedRxTV
Views:
414  1
ratings |
| Time:15:09 | More inScience & Technology |